Cytokinetics (CYTK) Competitors $51.86 -1.46 (-2.74%) As of 01:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CYTK vs. GMAB, VTRS, ASND, RDY, QGEN, BBIO, MRNA, ELAN, VRNA, and ROIVShould you be buying Cytokinetics stock or one of its competitors? The main competitors of Cytokinetics include Genmab A/S (GMAB), Viatris (VTRS), Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), BridgeBio Pharma (BBIO), Moderna (MRNA), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. Cytokinetics vs. Its Competitors Genmab A/S Viatris Ascendis Pharma A/S Dr. Reddy's Laboratories Qiagen BridgeBio Pharma Moderna Elanco Animal Health Verona Pharma PLC American Depositary Share Roivant Sciences Genmab A/S (NASDAQ:GMAB) and Cytokinetics (NASDAQ:CYTK) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings. Is GMAB or CYTK more profitable? Genmab A/S has a net margin of 37.53% compared to Cytokinetics' net margin of -707.17%. Genmab A/S's return on equity of 21.03% beat Cytokinetics' return on equity.Company Net Margins Return on Equity Return on Assets Genmab A/S37.53% 21.03% 16.98% Cytokinetics -707.17%N/A -45.52% Which has more volatility and risk, GMAB or CYTK? Genmab A/S has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Do analysts recommend GMAB or CYTK? Genmab A/S currently has a consensus target price of $39.25, indicating a potential upside of 40.50%. Cytokinetics has a consensus target price of $75.38, indicating a potential upside of 44.72%. Given Cytokinetics' stronger consensus rating and higher probable upside, analysts clearly believe Cytokinetics is more favorable than Genmab A/S.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genmab A/S 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.70Cytokinetics 0 Sell rating(s) 3 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.87 Do institutionals & insiders believe in GMAB or CYTK? 7.1% of Genmab A/S shares are held by institutional investors. 1.5% of Genmab A/S shares are held by insiders. Comparatively, 2.7% of Cytokinetics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has higher valuation & earnings, GMAB or CYTK? Genmab A/S has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenmab A/S$3.12B5.74$1.14B$1.9914.04Cytokinetics$18.47M337.47-$589.53M-$5.10-10.21 Does the media refer more to GMAB or CYTK? In the previous week, Cytokinetics had 7 more articles in the media than Genmab A/S. MarketBeat recorded 17 mentions for Cytokinetics and 10 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 1.29 beat Cytokinetics' score of 0.98 indicating that Genmab A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 11 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryGenmab A/S beats Cytokinetics on 10 of the 16 factors compared between the two stocks. Get Cytokinetics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CYTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYTK vs. The Competition Export to ExcelMetricCytokineticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.24B$3.14B$5.77B$10.15BDividend YieldN/A2.32%5.69%4.61%P/E Ratio-10.2221.4074.4425.99Price / Sales337.47298.78465.6391.46Price / CashN/A45.3337.0859.91Price / Book-45.309.6012.216.30Net Income-$589.53M-$53.32M$3.28B$270.75M7 Day Performance-1.74%0.53%1.21%3.36%1 Month Performance51.82%9.17%7.52%6.51%1 Year Performance-3.64%12.80%63.84%27.98% Cytokinetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYTKCytokinetics4.3132 of 5 stars$51.86-2.7%$75.38+45.4%-0.8%$6.22B$18.47M-10.19250Insider TradeGMABGenmab A/S3.9818 of 5 stars$24.87-1.0%$37.60+51.2%+6.2%$15.96B$3.26B12.502,682News CoveragePositive NewsVTRSViatris1.5982 of 5 stars$10.55+1.3%$10.40-1.4%-10.3%$12.30B$14.12B-3.6432,000Positive NewsASNDAscendis Pharma A/S3.1082 of 5 stars$194.27+0.2%$243.36+25.3%+75.0%$11.89B$393.54M-37.651,017Positive NewsRDYDr. Reddy's Laboratories2.484 of 5 stars$14.20-0.1%$16.95+19.4%-7.1%$11.85B$3.81B21.5127,811Positive NewsQGENQiagen4.468 of 5 stars$46.53+0.9%$49.69+6.8%+3.3%$10.34B$2.04B27.495,765Positive NewsBBIOBridgeBio Pharma4.4486 of 5 stars$51.76-1.5%$62.18+20.1%+87.9%$9.89B$235.81M-12.66400Positive NewsAnalyst ForecastMRNAModerna4.5036 of 5 stars$24.09-1.6%$42.88+78.0%-68.1%$9.37B$3.06B-3.205,800Positive NewsELANElanco Animal Health2.6536 of 5 stars$18.38-0.4%$17.33-5.7%+29.8%$9.13B$4.48B21.379,000Positive NewsHigh Trading VolumeVRNAVerona Pharma PLC American Depositary Share2.1761 of 5 stars$105.91+0.0%$109.00+2.9%+252.9%$8.67B$221.67M-106.9830Positive NewsROIVRoivant Sciences2.9462 of 5 stars$11.93-0.1%$16.50+38.3%+16.4%$8.15B$29.05M-17.04860News CoveragePositive NewsOptions Volume Related Companies and Tools Related Companies Genmab A/S Alternatives Viatris Alternatives Ascendis Pharma A/S Alternatives Dr. Reddy's Laboratories Alternatives Qiagen Alternatives BridgeBio Pharma Alternatives Moderna Alternatives Elanco Animal Health Alternatives Verona Pharma PLC American Depositary Share Alternatives Roivant Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYTK) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytokinetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
